

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Lamothe Jeffrey G.</u> (Last) (First) (Middle) 2401 4TH AVENUE SUITE 1050 (Street) SEATTLE WA 98121 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Aptevo Therapeutics Inc. [APVO]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) <p style="text-align: right;">SVP and CFO</p>
	3. Date of Earliest Transaction (Month/Day/Year) 02/28/2019	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/01/2019		M		7,318	A	(1)	77,194	D	
Common Stock	03/01/2019		F		2,170	D	\$1.57	75,024	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (right to buy)	\$1.52	02/28/2019		A		67,400		(2)	02/28/2029	Common Stock	67,400	\$0	67,400	D	
Restricted Stock Unit	(1)	03/01/2019		M		7,318		(3)	(3)	Common Stock	7,318	\$0	0	D	

Explanation of Responses:

- Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis.
- The option vests in three approximately equal annual installments beginning on February 28, 2020.
- The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. 7,320 shares of common stock underlying the RSUs vested on each of March 1, 2017 and March 1, 2018, and the remaining 7,318 shares vested on March 1, 2019.

/s/ Carl A. Valenstein, attorney-in-fact 03/04/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.